Century Therapeutics Inc banner

Century Therapeutics Inc
NASDAQ:IPSC

Watchlist Manager
Century Therapeutics Inc Logo
Century Therapeutics Inc
NASDAQ:IPSC
Watchlist
Price: 2.25 USD -0.44% Market Closed
Market Cap: $404.4m

During the last 3 months Century Therapeutics Inc insiders have not bought any shares, and sold 46.1k USD worth of shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Mar 12, 2026 by Russotti Gregory , who sold 25.7k USD worth of IPSC shares.

Last Transactions:
Carr Douglas
$-18k
Russotti Gregory
$-25.7k
Carr Douglas
$-626.4
Russotti Gregory
$-1.2k
Carr Douglas
$-588.5
Cowan Chad
$+49.3k
Pfeiffenberger Brent
$+30.4k
Russotti Gregory
$-279.8
Carr Douglas
$-136.7
Cowan Chad
$-2.7k
Pfeiffenberger Brent
$+17.3k
Pfeiffenberger Brent
$-14.7k
Carr Douglas
$-171.1
Russotti Gregory
$-269.5
Pfeiffenberger Brent
$-244
Carr Douglas
$-131.5
Carr Douglas
$-158.1
Farid Adrienne
$-343.3
Carr Douglas
$-3.1k
Pfeiffenberger Brent
$-295.5
Russotti Gregory
$-327.2
Pfeiffenberger Brent
$-16.1k
Farid Adrienne
$-563.2
Carr Douglas
$-162.3
Pfeiffenberger Brent
$-1.4k
Russotti Gregory
$-1.5k
Farid Adrienne
$-1.5k
Carr Douglas
$-762.6
Pfeiffenberger Brent
$-27.2k
Farid Adrienne
$-822.1
Carr Douglas
$-273.8
Carr Douglas
$-347.2
View All Transactions

During the last 3 months Century Therapeutics Inc insiders have not bought any shares, and sold 46.1k USD worth of shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Mar 12, 2026 by Russotti Gregory , who sold 25.7k USD worth of IPSC shares.

Sold
0-3
months
46.1k USD
2
3-6
months
18.1k USD
4
6-9
months
803.1 USD
3
9-12
months
20.9k USD
4
Bought
0-3
months
0
0 USD
3-6
months
2
96.9k USD
6-9
months
0
0 USD
9-12
months
0
0 USD

Century Therapeutics Inc
Insider Trading Chart

Century Therapeutics Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Century Therapeutics Inc
Last Insider Transactions

Global
Insiders Monitor

Century Therapeutics Inc
Glance View

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. The company is headquartered in Philadelphia, Pennsylvania and currently employs 170 full-time employees. The company went IPO on 2021-06-17. The firm is focused on developing transformative allogeneic, pluripotent stem cells (iPSC)-derived natural killer (NK) and T cell therapies to create products for the treatment of both solid tumor and hematological malignancies. Its Allo-Evasion technology is intended to prevent rejection of cell products by the host immune system, and manufacturing capabilities intended to minimize product development and supply risk. The firm's pipeline includes CNTY-101, CNTY-103, CNTY-102 and CNTY-104. The Company’s lead product candidate, CNTY-101, is focused on targeting B-cell lymphoma. CNTY-103 is designed to treat glioblastoma. CNTY-102 is designed to improve B-cell malignancy treatment. CNTY-104, is being developed to treat acute myeloid leukemia (AML). CAR design is a component of cell therapy product candidates. In addition to its programs, the Company is also actively engaged in a number of earlier stage discovery programs.

IPSC Intrinsic Value
1.43 USD
Overvaluation 36%
Intrinsic Value
Price $2.25

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett